Fig. 5
From: New clinical trial design in precision medicine: discovery, development and direction
The inhibition power of common multitarget TKIs on different targets. The IC50 (nM) for different targets in different tumor types of multitarget TKIs are shown. The application preference of multitarget TKIs in multi-cancer with common characteristics has been summarized
